WANT A PROFILE LIKE THIS?
Create my FREE Plan Or learn about other options
Luke Stockwin
PeerJ Author
135 Points

Contributions by role

Author 135

Contributions by subject area

Bioinformatics
Cell Biology
Genomics
Oncology

Luke H Stockwin

PeerJ Author

Summary

Leeds University, UK - PhD in cancer Immunobiology.
Oxford Glycosciences, UK - Proteomic characterization of cancer cell surface markers - with development of humanized therapeutic monoclonal antibodies.
FNLCR Developmental Therapeutic Program [DTP] mechanism group - Proteomic Identification of small-molecule response biomarkers, mechanistic studies of small molecules, transcriptomics of xenograft models and rare tumors.
FNLCR Patient-derived model [PDM] initiative - development of a platform for the rapid derivation and molecular characterization of cancer cell lines and CAFs from tumor biopsies and patient-derived xenografts.

Biochemistry Bioinformatics Biotechnology Cell Biology Computational Biology Genomics Molecular Biology Oncology Translational Medicine

Work details

Senior Scientist

Leidos Biomedical
September 2003 - April 2020
DCTD
2012 – Present: NCI Patient derived model initiative, Biological Testing Branch, Developmental Therapeutics Program, FNLCR [formerly NCI-Frederick]. Responsibility for the generation, characterization, purification [cell sorting] and genomic analysis of cell lines and CAFS derived from PDX tumors. Specifically, development of antibody panels for the characterization and enrichment [FACS/cell sorting] of tumor cells and CAFs from PDX tumors. Development of protocols for the maintenance of PDX-derived cell cultures [defined media, 2D/3D culture systems, Rho kinase inhibitors etc.]. Development of a simple and sensitive qRT-PCR assay for the detection of mouse mRNA in mixed cultures [for estimation of % mouse contamination]. Development of qRT-PCR array for the identification of human fibroblasts/endothelial and other mesenchymal cells. Genomic characterization of PDX cultures - Microarray analysis [U133 plus 2.0 and ST arrays], Immunocytochemistry, western blotting, RPPA antibody arrays.

PeerJ Contributions

  • Articles 1
June 19, 2020
Alveolar soft-part sarcoma (ASPS) resembles a mesenchymal stromal progenitor: evidence from meta-analysis of transcriptomic data
Luke H. Stockwin
https://doi.org/10.7717/peerj.9394 PubMed 32596059